Colesevelam hydrochloride (Cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

Archives of Internal Medicine

Volumn 159, Issue 16, 1999, Pages 1893-1900

  Davidson, Michael H ^a   Dillon, Maureen A ^b   Gordon, Bruce ^c   Jones, Peter ^d   Samuels, Julie ^e   Weiss, Stuart ^f   Isaacsohn, Jonathon ^g   Toth, Phillip ^h   Burke, Steven K ^b  

^a RADIANT RESEARCH   (United States)

^b GENZYME CORPORATION   (United States)

^c ROGOSIN INSTITUTE   (United States)

^d Baylor Clinic   (United States)

^e National Clinical Research Inc   (United States)

^f San Diego Arthritis Medical Clinic   (United States)

^g Metabolic and Atherosclerosis Research Center   (United States)

^h Midwest Institute for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; COLESEVELAM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROGEL; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALLYLAMINE; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIGESTIVE SYSTEM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPIDS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0033552130     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.16.1893     Document Type: Article

References (39)

1. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
2. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
3. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-39.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol lipoproteins and the risk of coronary heart disease. Ann Intern Med. 1971;74:1-12.
5. Martin MJ, Hulley SY, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-939.
6. Blackenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
7. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
8. Shepherd J, Cobbe ST, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
9. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
10. Grundy SM, Ahrens EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971;178:94-121.
11. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980; 302:1219-1222.
12. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease, clinical benefits and possible mechanisms of action. N Engl J Med. 1995;332: 512-521.
13. Pan HY, Devault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Therap. 1990;48:201-207.
14. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
15. American Heart Association. Step by Step: Eating to Lower Your High Blood Cholesterol. Bethesda, Md: National Institutes of Health; 1994. Publication NIH 94-2920.
16. Posner BM, Morgan JL. The 2D Food Portion Visual. Framingham, Mass: Nutrition Consulting Enterprises; 1992.
17. Myers G, Cooper G, Winn C, Smith S. The Centers for Disease Control - National Heart Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
18. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
19. Betteridge DJ, Bhatnager D, Bing RF, et al. Treatment of familial hypercholesterolaemia: United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ. 1992;304:1335-1338.
20. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
21. Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab. 1995;9:825-847.
22. Illingworth DR. How effective is drug therapy in heterozygous hypercholesterolemia? Am J Cardiol. 1993;72:54D-58D.
23. The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA. 1988:260: 359-366.
24. Wiklund O, Angelin B, Fager G, et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med. 1990;228:241-247.
25. Schectman G, Hiatt J. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium, and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol. 1993;71:759-765.
26. Hunninghake DB, Probstfield JL, Crow LO, Isaacson SO. Effect of colestipol and clofibrate on plasma lipids and lipoproteins in type IIa hyperlipoproteinemia. Metabolism. 1981;30:605-609.
27. Superko HR, Greenland P, Manchester RA, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. Am J Cardiol. 1992; 70:135-140.
28. Vecchio TJ, Linden CV, O'Connell MJ, Heilman J. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. Arch Intern Med. 1982;142: 721-723.
29. Lyons D, Webster J, Fowler G, Petrie JC. Colestipol at varying dosage interval in the treatment of moderate hypercholesterolaemia. B rJ Clin Pharmacol. 1994; 37:59-62.
30. Verzino EM, Kaplan B. Rational treatment for dyslipidemia. W V Med J. 1994; 90:58-61.
31. Farmer JA, Gotta AM Jr. Choosing the right lipid-regulating agent: a guide to selection. Drugs. 1996;52:649-661.
32. Hunninghake DB, Stein EA, Fraser Bremner W, Greenland P, Demke DM, Oliphant TH. Dose-response study oi colestipol tablets in patients with moderate hypercholesterolemia. Am J Ther. 1995;2:180-189.
33. Cooper EE, Michel AM. Colestipol hydrochloride, a new hypolipidemic drug: a two-year study. South Med J. 1975;68:303-309.
34. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients: effect on serum cholesterol and mortality. J Chronic Dis. 1978;31:5-14.
35. Hoogerbrugge N, Mol MJTM, Van Dormaal JJ, et al. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med. 1990;228:261-266.
36. Probstfield JL, Statland BE, Gorman L, et al. Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate. Metabolism. 1983;32:818-821.
37. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
38. Kuo PT, Wilson AC, Kostis JB, Moreyra AE. Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease. Am J Cardiol. 1986;57:43H-48H.
39. Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993; 269:3009-3014.